^
Association details:
| Biomarker: | SLC34A2 expression |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | ZW220 (Topoisomerase I inhibitor, NaPi2b-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1533 / 13 - ZW220, a novel NaPi2b-targeting antibody drug conjugate bearing a topoisomerase 1 inhibitor payload
Published date:
03/15/2023
Excerpt:
In vivo, the anti-tumor activity of ZW220 was evaluated in a panel of cell line derived xenograft (CDX) models and ovarian patient derived xenograft (PDX) models featuring a range of NaPi2b expression….The treatment of a panel of ovarian PDXs with a single dose of 6 mg/kg of ZW220 resulted in robust tumor growth inhibition...These results support the potential of ZW220 as a novel therapeutic agent which may help address unmet medical need in patients with NaPi2b-expressing tumors.
